Cargando…
4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 virus Rigvir administered intramuscularly with a 4-week recovery period
The oncolytic ECHO-7 virus Rigvir was registered in Latvia in 2004 and later in Georgia, Armenia and Uzbekistan. No severe adverse events have been observed. During drug development good laboratory practice (GLP) pre-clinical toxicology studies are generally required by regulatory agencies. Since su...
Autores principales: | Piwoni, Katarzyna, Jaeckel, Gilta, Rasa, Agnija, Alberts, Pēteris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840795/ https://www.ncbi.nlm.nih.gov/pubmed/33537211 http://dx.doi.org/10.1016/j.toxrep.2021.01.009 |
Ejemplares similares
-
Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines
por: Tilgase, Andra, et al.
Publicado: (2020) -
Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report
por: Proboka, Guna, et al.
Publicado: (2018) -
ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report
por: Jaunalksne, Inta, et al.
Publicado: (2020) -
A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir(®)
por: Ismailov, Zaurbek, et al.
Publicado: (2019) -
Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery
por: Tilgase, Andra, et al.
Publicado: (2018)